These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 10720881

  • 21. Blockade of angiotensin II type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mREN2)27 rats via adrenocortical steroid-independent mechanisms.
    Rossi GP, Sacchetto A, Rizzoni D, Bova S, Porteri E, Mazzocchi G, Belloni AS, Bahcelioglu M, Nussdorfer GG, Pessina AC.
    Arterioscler Thromb Vasc Biol; 2000 Apr; 20(4):949-56. PubMed ID: 10764658
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Antihypertensive effect of a non-peptide angiotensin II receptor antagonist, MK954, in patients with essential hypertension].
    Hagino T, Abe K, Tsunoda K, Yoshinaga K.
    Nihon Jinzo Gakkai Shi; 1992 Feb; 34(2):133-40. PubMed ID: 1588765
    [Abstract] [Full Text] [Related]

  • 25. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives.
    Tropeano AI, Boutouyrie P, Pannier B, Joannides R, Balkestein E, Katsahian S, Laloux B, Thuillez C, Struijker-Boudier H, Laurent S.
    Hypertension; 2006 Jul; 48(1):80-6. PubMed ID: 16702490
    [Abstract] [Full Text] [Related]

  • 26. Role of the renin-angiotensin system in hypertension in the elderly.
    Nagano M, Higaki J, Mikami H, Ogihara T.
    Blood Press Suppl; 1994 Jul; 5():130-3. PubMed ID: 7889195
    [Abstract] [Full Text] [Related]

  • 27. Effects of the new angiotensin II type 1 receptor antagonist KRH-594 on several types of experimental hypertension.
    Inada Y, Murakami M, Kaido K, Nakao K.
    Arzneimittelforschung; 1999 Jan; 49(1):13-21. PubMed ID: 10028373
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease.
    von Vigier RO, Zberg PM, Teuffel O, Bianchetti MG.
    Eur J Pediatr; 2000 Aug; 159(8):590-3. PubMed ID: 10968237
    [Abstract] [Full Text] [Related]

  • 30. [Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
    Coca A, Giner V.
    Rev Esp Cardiol; 1999 Aug; 52 Suppl 3():53-8. PubMed ID: 10614150
    [Abstract] [Full Text] [Related]

  • 31. Effect of angiotensin receptor blockade on central haemodynamics in essential hypertension: results of a randomised trial.
    Schneider MP, Delles C, Klingbeil AU, Ludwig M, Kolloch RE, Krekler M, Stumpe KO, Schmieder RE.
    J Renin Angiotensin Aldosterone Syst; 2008 Mar; 9(1):49-56. PubMed ID: 18404609
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review.
    Dahlöf B.
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S37-44. PubMed ID: 8583480
    [Abstract] [Full Text] [Related]

  • 34. Improvement of coronary microvascular function after Angiotensin receptor blocker treatment with irbesartan in patients with systemic hypertension.
    Lethen H, Tries HP, Kersting S, Bramlage P, Lambertz H.
    J Clin Hypertens (Greenwich); 2011 Mar; 13(3):155-61. PubMed ID: 21366846
    [Abstract] [Full Text] [Related]

  • 35. The peripheral renin-angiotensin system is not involved in the hypertension of sheep exposed to prenatal dexamethasone.
    Peers A, Campbell DJ, Wintour EM, Dodic M.
    Clin Exp Pharmacol Physiol; 2001 Apr; 28(4):306-11. PubMed ID: 11251645
    [Abstract] [Full Text] [Related]

  • 36. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension.
    Grossman E, Peleg E, Carroll J, Shamiss A, Rosenthal T.
    Am J Hypertens; 1994 Dec; 7(12):1041-4. PubMed ID: 7702796
    [Abstract] [Full Text] [Related]

  • 37. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
    Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group.
    N Engl J Med; 2001 Sep 20; 345(12):851-60. PubMed ID: 11565517
    [Abstract] [Full Text] [Related]

  • 38. Lack of association between renin-angiotensin system, gene polymorphisms, and wall thickness of the radial and carotid arteries.
    Girerd X, Hanon O, Mourad JJ, Boutouyrie P, Laurent S, Jeunemaitre X.
    Hypertension; 1998 Sep 20; 32(3):579-83. PubMed ID: 9740630
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.
    Ruilope L.
    J Hypertens Suppl; 1997 Dec 20; 15(7):S15-20. PubMed ID: 9532516
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.